the at least one symptom is selected from the group consisting of: impaired or abnormal gait, neuronal oxidative stress, dementia, tremor, impaired balance, weakness, and personality changes
[1] [2] This dual-incretin receptor agonist works by enhancing insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
Development of Novel Specific and Sensitive ELISAs for Proglucagon-Derived Peptides
Both medication classes can influence cardiovascular parameters and glucose metabolism in ways that may require monitoring and dose adjustments
However, 503A pharmacies compounding patient-specific preparations on a prescription-by-prescription basis occupy a different regulatory category and may continue in Michigan depending on evolving FDA enforcement guidance